ArticleHemaSphere2024

Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia.

Mei-Jing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.